SpringerLink
Log in

Cancer Pathology

  • Chapter
  • First Online:
Clinical Ophthalmic Oncology

  • 778 Accesses

Abstract

The term neoplasm, commonly used interchangeably with tumor, refers to an abnormal growth of new cells. This growth may be benign without potential for metastasis or malignant with a risk for metastatic spread to other anatomical sites. Both types of neoplasm might lead to morbidity and death, depending on factors such as the cell of origin, immunological responses, nutritional conditions, and extent and location of the growth. In this chapter, characteristic differences between different types of benign and malignant tumors are described. Further, we elaborate on their genesis and basis for survival and growth, as well as on methods for clinical tumor tissue sampling and diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  Google Scholar 

  2. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331:1553–8.

    Article  CAS  Google Scholar 

  3. Korkola J, Gray JW. Breast cancer genomes – form and function. Curr Opin Genet Dev. 2010;20:4–14.

    Article  CAS  Google Scholar 

  4. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328–37.

    Article  CAS  Google Scholar 

  5. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611–22.

    Article  CAS  Google Scholar 

  6. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31:9–18.

    Article  CAS  Google Scholar 

  7. Teng MW, Swann JB, Koebel CM, et al. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008;84:988–93.

    Google Scholar 

  8. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–26.

    Google Scholar 

  9. Shields JD, Kourtis IC, Tomei AA, et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010;328:749–52.

    Google Scholar 

  10. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61.

    Article  CAS  Google Scholar 

  11. Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32(2):204–220.e215.

    Google Scholar 

  12. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:537–48.

    Article  CAS  Google Scholar 

  13. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8:671–82.

    Article  CAS  Google Scholar 

  14. Onken MD, Ehlers JP, Worley LA, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006;66:4602–9.

    Google Scholar 

  15. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009;1:a003129.

    Article  Google Scholar 

  16. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324–37.

    Article  CAS  Google Scholar 

  17. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72–6.

    Article  CAS  Google Scholar 

  18. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–58.

    Article  CAS  Google Scholar 

  19. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.

    Article  CAS  Google Scholar 

  20. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–9.

    Google Scholar 

  21. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68.

    Google Scholar 

  22. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.

    Article  CAS  Google Scholar 

  23. Foss AJ, Alexander RA, Jefferies LW, et al. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900–3.

    Google Scholar 

  24. Al-Mehdi AB, Tozawa K, Fisher AB, et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000;6:100–2.

    Google Scholar 

  25. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.

    Article  CAS  Google Scholar 

  26. Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014;134:1207–13.

    Google Scholar 

  27. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–4.

    Google Scholar 

  28. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.

    Google Scholar 

  29. Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011;71:2455–65.

    Google Scholar 

  30. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91–102.

    Google Scholar 

  31. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–4.

    Article  CAS  Google Scholar 

  32. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev. 2008;18:48–53.

    Article  CAS  Google Scholar 

  33. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.

    Article  CAS  Google Scholar 

  34. Seregard S, Spangberg B, Juul C, et al. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology. 1998;105:485–91.

    Google Scholar 

  35. Seregard S, Oskarsson M, Spangberg B. PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma. Invest Ophthalmol Vis Sci. 1996;37:1451–8.

    CAS  PubMed  Google Scholar 

  36. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand. 1995;73:340–4.

    Article  CAS  Google Scholar 

  37. Makitie T, Summanen P, Tarkkanen A, et al. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414–21.

    Google Scholar 

  38. Char DH, Kemlitz AE, Miller T. Intraocular biopsy. Ophthalmol Clin North Am. 2005;18:177–85, x.

    Article  Google Scholar 

  39. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422–30.

    Google Scholar 

  40. Shields JA, Shields CL, Ehya H, et al. Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology. 1993;100:1677–84.

    Google Scholar 

  41. Bechrakis NE, Foerster MH, Bornfeld N. Biopsy in indeterminate intraocular tumors. Ophthalmology. 2002;109:235–42.

    Article  Google Scholar 

  42. Spencer JM, Nossa R, Tse DT, et al. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001;44:1004–9.

    Google Scholar 

  43. Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology. 2003;110:2011–8.

    Google Scholar 

  44. Folberg R, Salomao D, Grossniklaus HE, et al. Recommendations for the reporting of tissues removed as part of the surgical treatment of common malignancies of the eye and its adnexa. Am J Surg Pathol. 2003;27:999–1004.

    Google Scholar 

  45. Stålhammar G, Fuentes Martines N, Lippert M, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29:318–29.

    Google Scholar 

  46. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Google Scholar 

  47. Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205–9.

    Google Scholar 

  48. Onken MD, Worley LA, Char DH, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596–603.

    Google Scholar 

  49. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25:234–9.

    Google Scholar 

  50. Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2011;118:396–401.

    Google Scholar 

  51. Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41–8.

    Google Scholar 

  52. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17:6574–81.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmic Pathology and Oncology Service and Department of Clinical Neuroscience, St. Erik Eye Hospital and Karolinska Institutet, Stockholm, Sweden

    Gustav Stålhammar, Katarina Bartuma, Charlotta All-Eriksson & Stefan Seregard

Authors
  1. Gustav Stålhammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katarina Bartuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charlotta All-Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Seregard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gustav Stålhammar .

Editor information

Editors and Affiliations

  1. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

    Arun D. Singh

  2. Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

    Bertil E. Damato

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Stålhammar, G., Bartuma, K., All-Eriksson, C., Seregard, S. (2019). Cancer Pathology. In: Singh, A., Damato, B. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-04489-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-04489-3_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-04488-6

  • Online ISBN: 978-3-030-04489-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation